Role of Renal Sympathetic Nerves in GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Exendin-4-Mediated Diuresis and Natriuresis in Diet-Induced Obese Rats

被引:9
|
作者
Liu, Xuefei [1 ]
Patel, Kaushik P. [2 ]
Zheng, Hong [1 ]
机构
[1] Univ South Dakota, Div Basic Biomed Sci, Sanford Sch Med, Vermillion, SD 57069 USA
[2] Univ Nebraska Med Ctr, Dept Cellular & Integrat Physiol, Omaha, NE USA
来源
基金
美国国家卫生研究院;
关键词
glucagon-like peptide-1; neprilysin; obesity; renal nerve; sodium retention; BLOOD-PRESSURE; HEART-FAILURE; SODIUM-EXCRETION; HYPERTENSION; NEPRILYSIN; LIRAGLUTIDE; EXPRESSION; IMPACT; INJURY;
D O I
10.1161/JAHA.121.022542
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The gut-derived hormone GLP-1 (glucagon-like peptide-1) exerts beneficial effects against established risk factors for chronic kidney disease. GLP-1 influences renal function by stimulating diuresis and natriuresis and thus lowering arterial blood pressure. The role of the sympathetic nervous system has been implicated as an important link between obesity with elevated arterial pressure and chronic kidney disease. The primary aim of this study was to determine the contribution of renal sympathetic nerves on intrapelvic GLP-1-mediated diuresis and natriuresis in high-fat diet (HFD)-induced obese rats. Methods and Results Obesity was induced in rats by HFD for 12 weeks, followed by either surgical bilateral renal denervation or chronic subcutaneous endopeptidase neprilysin inhibition by sacubitril for a week. Diuretic and natriuretic responses to intrapelvic administration of the GLP-1R (GLP-1 receptor) agonist exendin-4 were monitored in anesthetized control and HFD rats. Renal GLP-1R expression and neprilysin expression and activity were measured. The effects of norepinephrine on the expression of GLP-1R and neprilysin in kidney epithelial LLC-PK1 cells were also examined. We found that diuretic and natriuretic responses to exendin-4 were significantly reduced in the HFD obese rats compared with the control rats (cumulative urine flow at 40 minutes, 387 +/- 32 versus 650 +/- 65 mu L/gkw; cumulative sodium excretion at 40 minutes, 42 +/- 5 versus 75 +/- 10 mu Eq/gkw, P<0.05). These responses in the HFD rats were restored after ablation of renal nerves (cumulative urine flow at 40 minutes, 625 +/- 62 versus 387 +/- 32 mu L/gkw; cumulative sodium excretion at 40 minutes, 70 +/- 9 versus 42 +/- 5 mu Eq/gkw, P<0.05). Renal denervation induced significant reductions in arterial pressure and heart rate responses to intrapelvic GLP-1 in the HFD rats. Renal denervation also significantly increased the GLP-1R expression and reduced neprilysin expression and activity in renal tissues from the HFD rats. Chronic subcutaneous neprilysin inhibition by sacubitril increased GLP-1-induced diuretic and natriuretic effects in the HFD rats. Finally, exposure of the renal epithelial cells to norepinephrine in vitro led to downregulation of GLP-1R expression but upregulation of neprilysin expression and activity. Conclusions These results suggest that renal sympathetic nerve activation contributes to the blunted diuretic and natriuretic effects of GLP-1 in HFD obese rats. This study provides significant novel insight into the potential renal nerve-neprilysin-GLP-1 pathway involved in renal dysfunction during obesity that leads to hypertension.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Discovery of a Potent, Orally Efficacious Small Molecule Agonist of Glucagon-Like Peptide-1 (GLP-1) Receptor
    Bearss, David J.
    Lin, Chenyu
    Medley, Kyle
    Vankayalapati, Hariprasad
    DIABETES, 2024, 73
  • [22] A mechanism for agonist activation of the glucagon-like peptide-1 (GLP-1) receptor through modelling & molecular dynamics
    Santiago, Carla Gomez
    Paci, Emanuele
    Donnelly, Dan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 498 (02) : 359 - 365
  • [23] From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role in Prostate Cancer
    Alhajahjeh, Abdulrahman
    Al-Faouri, Raad
    Bahmad, Hisham F.
    Bader, Taima'
    Dobbs, Ryan W.
    Abdulelah, Ahmed A.
    Abou-Kheir, Wassim
    Davicioni, Elai
    Lee, David I.
    Shahait, Mohammed
    CANCERS, 2024, 16 (08)
  • [24] The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis
    Li, Ya-Kun
    Ma, Dong-Xia
    Wang, Zhi-Min
    Hu, Xiao-Fan
    Li, Shang-Lin
    Tian, Hong-Zhe
    Wang, Meng-Jun
    Shu, Yan-Wen
    Yang, Jun
    PHARMACOLOGICAL RESEARCH, 2018, 131 : 102 - 111
  • [25] Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome
    Tzotzas, Themistoklis
    Karras, Spyridon N.
    Katsiki, Niki
    CURRENT VASCULAR PHARMACOLOGY, 2017, 15 (03) : 218 - 229
  • [26] Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
    Unger J.R.
    Parkin C.G.
    Diabetes Therapy, 2011, 2 (1) : 29 - 39
  • [27] Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands
    Tanday, Neil
    Flatt, Peter R.
    Irwin, Nigel
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 526 - 541
  • [28] Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists
    Mabilleau, Guillaume
    Pereira, Marie
    Chenu, Chantal
    JOURNAL OF ENDOCRINOLOGY, 2018, 236 (01) : R29 - R42
  • [29] CLONING AND FUNCTIONAL EXPRESSION OF THE HUMAN GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR
    DILLON, JS
    TANIZAWA, Y
    WHEELER, MB
    LENG, XH
    LIGON, BB
    RABIN, DU
    YOOWARREN, H
    PERMUTT, MA
    BOYD, AE
    ENDOCRINOLOGY, 1993, 133 (04) : 1907 - 1910
  • [30] IDENTIFICATION ON PREVENTIVE MECHANISM OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONIST FOR ATHEROSCLEROSIS MODEL
    Lee, S. -G.
    Kim, J. -S.
    Lee, H. -J.
    Lee, S. -J.
    Oh-Hyun, L.
    Kim, C. -K.
    ATHEROSCLEROSIS, 2023, 379